0     

Agyei P, Chen M, Guo Y, Perez CA, Dubey D, Gupta RK. Pearls & Oy-sters: KLHL11 IgG paraneoplastic-associated hearing loss and rhombencephalitis in a woman with metastatic Mullerian tumor. Neurology. 2024;102(7):e209187. PMID: 38484225.

0     

Rojas JI, Gracia F, Parciak T, Alonso R, Becker J, Trevino-Frenk I, et al. [Core data set for real world data in multiple sclerosis: Customization for Latin America from a global task force recommendation]. Rev Neurol. 2024;78(7):185-97. PMID: 38502167.

0     

Román MS, González FM, Bardoneschi L, Herrera Fernández M, Eizaguirre MB, Cáceres F, et al. Contextual factors matter: The role of social support in work-related difficulties and employment status in persons with multiple sclerosis. Sclerosis. 2024;2(1):65-76. DOI: 10.3390/sclerosis2010005.

0     

Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Correction to: Multiple aclerosis and neuromyelitis optica spectrum disorder: Onset following acute COVID-19 infection, a case series. Neurol Ther. 2023;12(2):701. PMID: 36821074.

0     

Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Multiple Sclerosis and neuromyelitis optica spectrum disorder: Onset following acute COVID-19 infection, a case series. Neurol Ther. 2023;12(1):319-27. PMID: 36399224.

0     

Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023;43(6):473-84. PMID: 37157135.

0     

Gupta RK, Reddy TA, Gupta A, Samant R, Perez CA, Haque A. An ecchordosis physaliphora, a rare entity, involving the central nervous system: A systematic review of the literature. Neurol Int. 2023;15(4):1200-11. PMID: 37873832.

0     

Li J, Huang Y, Hutton GJ, Aparasu RR. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023;11:100307. PMID: 37554927.

0     

Moore MZ, Perez CA, Hutton GJ, Patel H, Cuascut FX. Health disparities in multiple sclerosis among Hispanic and Black populations in the United States. Biomedicines. 2023;11(4):. PMID: 37189845.

0     

Orlando CM, Perez CA, Agyei P, Elsehety M, Singh SK, Thomas J, et al. Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis. Mult Scler. 2023;29(10):1304-15. PMID: 37435828.

0     

Pérez CA, Cuascut FX, Hutton GJ. Immunopathogenesis, diagnosis, and treatment of multiple sclerosis: A clinical update. Neurol Clin. 2023;41(1):87-106. PMID: 36400561.

0     

Rivera VM. Neuromyelitis optica spectrum disorder: Redefining an old disease. Present and future challenges. J Integr Neurosci. 2023;22(6):139. PMID: 38176944.

0     

Alkabie S, Tanweer O, Hutton GJ, Cuascut FX. Clinical reasoning: A 57-year-old man with stepwise progressive paraparesis, sensory loss, urinary retention, and constipation. Neurology. 2022;98(5):e555-60. PMID: 34799458.

0     

Alvarez MR, Gurung A, Velayndhan V, Cuascut F, Alkabie S, Freeman L, et al. Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): A retrospective analysis in two inner-city hospitals. J Neurol Sci. 2022;443:120460. DOI: 10.1016/j.jns.2022.120460.

0     

Choudhury NA, Castrodad-Molina RM, Hutton GJ, Cuascut FX. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022;58:103498. PMID: 35007821.

0     

Gracia F, Ramírez D, Parajeles-Vindas A, Díaz A, Díaz de la Fé A, Sánchez NER, et al. Neuromyelitis optica spectrum disorder in Central America and the Caribbean: A multinational clinical characterization study. Neurol Int. 2022;14(1):284-93. DOI: 10.3390/neurolint14010023.

0     

Gupta RK, Haque A, Reddy TA, Perez CA. A patient with Erdheim-Chester disease limited to central nervous system. Neurol Int. 2022;14(3):678-82. PMID: 36135991.

0     

Haque A, Perez CA, Reddy TA, Gupta RK. Erdheim-Chester disease with isolated CNS involvement: A systematic review of the literature. Neurol Int. 2022;14(3):716-26. PMID: 36135995.

0     

Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. Factors associated with switching from injectable to oral disease modifying agents among patients with multiple sclerosis. Mult Scler Relat Disord. 2022;60:103703. PMID: 35278846.

0     

Li J, Zakeri M, Hutton GJ, Aparasu RR. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022;66:104019. PMID: 35839614.

0     

Nascimento FA, Moore M, Olandoski M, Gavvala JR. Short-term effectiveness of a condensed series of standard EEG lectures for adult neurology residents. Epileptic Disord. 2022;24(2):397-403. PMID: 35067482.

0     

Talwar A, Earla JR, Hutton GJ, Aparasu RR. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103308. PMID: 35158421.

0     

Alkabie S, Castrodad-Molina R, Heck KA, Mandel J, Hutton GJ. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021;50:102877. PMID: 33711579.

0     

Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: A review. JAMA Neurol. 2021;78(12):1515-24. PMID: 34605866.

0     

Cristiano E, Abad P, Becker J, Carra A, Correale J, Flores J, et al. Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation. J Neurol Sci. 2021;429:118072. PMID: 34509134.

0     

Cuascut FX, Alkabie S, Hutton GJ. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021;53:103072. PMID: 34139459.

0     

Earla JR, Hutton GJ, Thornton DJ, Chen H, Johnson ML, Aparasu RR. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021;41(5):440-50. PMID: 33641232.

0     

Hafeez MU, Moore M, Hafeez K, Jankovic J. Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021;21(8):881-94. PMID: 34281468.

0     

Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, et al. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;54:103149. PMID: 34284316.

0     

Perez CA, Lincoln JA. Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study. Mult Scler Relat Disord. 2021;56:103248. PMID: 34536772.

0     

Perez CA, Salehbeiki A, Zhu L, Wolinsky JS, Lincoln JA. Assessment of racial/ethnic disparities in volumetric MRI correlates of clinical disability in multiple sclerosis: A preliminary study. J Neuroimaging. 2021;31(1):115-23. PMID: 32949483.

0     

Perez CA, Zhang GQ, Li X, Huang Y, Lincoln JA, Samudralwar RD, et al. COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study. Mult Scler Relat Disord. 2021;55:103217. PMID: 34418735.

0     

Rivera VM, Hamuy F, Rivas V, Gracia F, Rojas JI, Bichuetti DB, et al. Status of the neuromyelitis optica spectrum disorder in Latin America. Mult Scler Relat Disord. 2021;53:103083. DOI: https://doi.org/10.1016/j.msard.2021.103083.

0     

Rivera VM. Editorial of special issue "Multiple sclerosis: Diagnosis and treatment II". Biomedicines. 2021;9(11):. PMID: 34829833.

0     

Rojas JI, Carnero Contentti E, Abad P, Aguayo A, Alonso R, Bauer J, et al. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Mult Scler Relat Disord. 2021;53:103038. PMID: 34090128.

0     

Andriescu EC, Russo SN, Perez CA. Teaching neuroimages: Infantile-onset Krabbe disease with tigroid appearance of the white matter. Neurology. 2020;94(18):e1964-e1965. PMID: 32269112.

0     

Dixon GA, Perez CA. Multiple sclerosis and the choroid plexus: Emerging concepts of disease immunopathophysiology. Pediatr Neurol. 2020;103:65-75. PMID: 31780202.

0     

Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Factors associated with prescribing oral disease modifying agents in multiple sclerosis: A real-world analysis of electronic medical records. Mult Scler Relat Disord. 2020;45:102334. PMID: 32629400.

0     

Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis. Patient Prefer Adherence. 2020;14:2187-99. PMID: 33177813.

0     

Earla JR, Paranjpe R, Kachru N, Hutton GJ, Aparasu RR. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020;16(12):1670-6. PMID: 32171597.

0     

Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020;26(6):741-9. PMID: 32463779.

0     

Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines. 2020;8(4):. PMID: 32231060.

0     

Mercado V, Dongarwar D, Fisher K, Salihu HM, Hutton GJ, Cuascut FX. Multiple sclerosis in a multi-ethnic population in Houston, Texas: A retrospective analysis. Biomedicines. 2020;8(12):. PMID: 33255552.

0     

Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. PMID: 32498033.

0     

Perez CA, Agyei P, Gogia B, Harrison R, Samudralwar R. Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. J Neuroimmunol. 2020;339:577124. PMID: 31837635.

0     

Perez CA, Patnaik A, Oommen S, Redko A, Mathis SB. Tumefactive demyelinating lesions in children: A rare case of conus medullaris involvement and systematic review of the literature. J Child Neurol. 2020;35(10):690-9. PMID: 32552343.

0     

Perez CA, Shah EG, Butler IJ. Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus" and review of the literature. J Neuroimmunol. 2020;342:577197. PMID: 32126315.

0     

Perez CA. Looking ahead: The risk of neurologic complications due to COVID-19. Neurol Clin Pract. 2020;10(4):371-4. PMID: 32983618.

0     

Rivera VM, Gracia F, Diaz A. Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemia. Neurologia. 2020;35(9):705-6. PMID: 32893070.

1

Wang KY, Carlton J, Guffey D, Hutton GJ, Moron FE. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020;59(1):13-20. PMID: 31715512.

22

Cuascut FX, Hutton GJ. Stem cell-based therapies for multiple sclerosis: Current perspectives. Biomedicines. 2019;7(2):. PMID: 30935074.

0     

Perez CA, Garcia-Tarodo S, Troxell R. MRI-negative myelitis associated with myelin oligodendrocyte glycoprotein antibody spectrum demyelinating disease. Child Neurol Open. 2019;6:2329048X19830475. PMID: 30800700.

1

Rivera VM. Biosimilar drugs for multiple sclerosis: An unmet international need or a regulatory risk? Neurol Ther. 2019;8(2):177-84. PMID: 31313222.

0     

Wyrostek S, Chakrabarti S, Baldwin K, Avila JD. A case of hypertrophic pachymeningitis associated with immunoglobulin-G4 and c-ANCA. Case Rep Neurol. 2019;11(3):290-4. PMID: 31762760.

0     

Rivera VM. Multiple sclerosis as a universal disease and the challenges to immigrants in high prevalence countries. Eur J Neurol. 2018;25(4):612-3. PMID: 29341368.

10

Rivera VM. Multiple sclerosis: a global concern with multiple challenges in an era of advanced therapeutic complex molecules and biological medicines. Biomedicines. 2018;6(4):. PMID: 30513578.

0     

Rivera VM. Multiple sclerosis: depression and disability are globally shared issues of concern. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):12. DOI: 10.20517/2347-8659.2018.16.

0     

Seifan A, Shih C, Hackett K, Pensack MJ, Schelke MW, Lin M, et al. Detection of neurodevelopmental diversity in memory clinics - Validation of a self-report measure. Res Dev Disabil. 2018;77:60-7. PMID: 29660590.

0     

Yeo CJJ, Hutton GJ, Fung SH. Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year. Radiol Case Rep. 2018;13(5):1030-5. PMID: 30228838.

85

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-52. PMID: 28148635.

0     

Nelson F, Akhtar MA, Zuniga E, Perez CA, Hasan KM, Wilken J, et al. Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis. Mult Scler. 2017;23(6):836-47. PMID: 27613119.

0     

Rivera VM, Macias MA. Access and barriers to MS care in Latin America. Mult Scler J Exp Transl Clin. 2017;3(1):2055217317700668. DOI: doi:10.1177/2055217317700668.

0     

Rivera VM. Medicinal cannabis: Cultural, societal and regulatory challenges in the Americas. Ann Forensic Res Anal. 2017;4(1):1038.

10

Rivera VM. Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep. 2017;17(8):57. PMID: 28639238.

0     

Jaumotte JD, Wyrostek SL, Zigmond MJ. Protection of cultured dopamine neurons from MPP(+) requires a combination of neurotrophic factors. Eur J Neurosci. 2016;44(1):1691-9. PMID: 27098376.

2

Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016;369:51-2. PMID: 27653865.

0     

Perez CA, Evangelista M. Evaluation and management of Tolosa-Hunt syndrome in children: A clinical update. Pediatr Neurol. 2016;62:18-26. PMID: 27473647.

0     

Perez CA, Garcia SS, Yu RD. Extrapyramidal symptoms as a result of risperidone discontinuation during combination therapy with methylphenidate in a pediatric patient. J Child Adolesc Psychopharmacol. 2016;26(2):182. PMID: 26871198.

0     

Rivera-Olmos VM, Parra-Bernal MC. [Cannabis: Effects in the central nervous system. Therapeutic, societal and legal consequences]. Rev Med Inst Mex Seguro Soc. 2016;54(5):626-34. PMID: 27428345.

0     

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145-52. PMID: 25681448.

115

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159-69. PMID: 25546364.

0     

Pérez CA, McMann DE, Mazur L, Murphy JR, Degaffe G. What's causing this teenager's chest pain and syncope symptoms? Consultant. 2015;14(9):418-21.

0     

Pérez CA. Hepatoblastoma associated with Sotos syndrome. Consultant. 2015;14(10):475-6.

0     

Pérez CA. What's the cause of this girl's widespread papulovesicular rash? Consultant. 2015;14(7):294-7.

9

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: A randomized controlled trial. Int J MS Care. 2015;17(3):138-45. PMID: 26052259.

0     

Yu R, Pérez CA, Evangelista M. What is causing this neonate's intractable postprandial vomiting? Consultant. 2015;15(5):263-5.

0     

Hutton J, Hutton GJ. Congenital rubella with autism and evidence of a remote stroke. J Vaccines Vaccin. 2014;5:258. DOI: 10.4172/2157-7560.1000258.

0     

Parmar MS, Jaumotte JD, Wyrostek SL, Zigmond MJ, Cavanaugh JE. Role of ERK1, 2, and 5 in dopamine neuron survival during aging. Neurobiol Aging. 2014;35(3):669-79. PMID: 24411019.

16

Rivera VM, Medina MT, Duron RM, Macias MA. Multiple sclerosis care in Latin America. Neurology. 2014;82(18):1660-1. PMID: 24799516.

4

Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, et al. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord. 2014;3(3):408-12. PMID: 25876482.

0     

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-40. PMID: 23424159.

5

Macias-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013;113(4):415-20. PMID: 23670405.

25

Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013;13:80. PMID: 23841877.

7

Abad P, Nogales-Gaete J, Rivera V, Cristiano E, Hamuy F, Oehninger C, et al. [LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. Rev Neurol. 2012;55(12):737-48. PMID: 23233142.

55

Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012;242(1-2):39-46. PMID: 22112394.

0     

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-28. PMID: 23122652.

0     

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-39. PMID: 23122650.

0     

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97. PMID: 22992072.

0     

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825-34. PMID: 22383228.

0     

Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011;13(2):91-3. PMID: 24453710.

0     

Busch SA, Hamilton JA, Horn KP, Cuascut FX, Cutrone R, Lehman N, et al. Multipotent adult progenitor cells prevent macrophage-mediated axonal dieback and promote regrowth after spinal cord injury. J Neurosci. 2011;31(3):944-53. PMID: 21248119.

4

Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther. 2011;11(7):961-7. PMID: 21563876.

12

Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77(5):505-7. PMID: 21775738.

35

Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4(1):3-14. PMID: 21339904.

0     

Busch SA, Horn KP, Cuascut FX, Hawthorne AL, Bai L, Miller RH, et al. Adult NG2+ cells are permissive to neurite outgrowth and stabilize sensory axons during macrophage-induced axonal dieback after spinal cord injury. J Neurosci. 2010;30(1):255-65. PMID: 20053907.

22

Cohen BA, Rivera VM. PRISMS: The story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010;26(4):827-38. PMID: 20121658.

0     

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15. PMID: 20089954.

28

Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010;4:219. PMID: 21152340.

8

Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):751-7. PMID: 20874252.

0     

Hutton GJ. Vitamin D and MS: implications for patient care. Pract Neurol. 2010;9:22-4.

1

Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2010;74(10):864. PMID: 20211915.

72

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-41. PMID: 19204263.

0     

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-71. PMID: 19847908.

4

Hutton GJ, Avila M, Suarez GA. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009;111(3):309-10. PMID: 19036497.

0     

Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT Investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study. Neurology. 2009;73(18):1493-500. PMID: 19884577.

12

Rivera VM. Multiple sclerosis in Latin America: Reality and challenge. Neuroepidemiology. 2009;32(4):294-5. PMID: 19246934.

0     

Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, et al. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science. 2009;326(5952):592-6. PMID: 19833921.

722

CAMMS Trial Investigators , Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801. PMID: 18946064.

18

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, et al. Avonex Combination Trial in relapsing--remitting MS: Rationale, design and baseline data. Mult Scler. 2008;14(3):370-82. PMID: 18208877.

132

Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039-47. PMID: 18838462.

6

Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, et al. Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? Brain. 2008;131(Pt 2):e89; author reply e90. PMID: 17908695.

343

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-32. PMID: 18541792.

119

Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-82 e5. PMID: 17976727.

2

Suarez Zambrano GA, Hutton GJ. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008;65(10):1388-9. PMID: 18852359.

0     

Cristiano E, Arcega R, Correale J, Gabbay AA, Lander-Delgado R, Macias-Islas MA, et al. [Recommendations for optimising the treatment of multiple sclerosis in Latin America]. Rev Neurol. 2007;44(8):494-8. PMID: 17455164.

10

Ordonez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin Neurol Neurosurg. 2007;109(1):102-5. PMID: 16624483.

0     

Rivera-Olmos VM, Avila MC. [Multiple sclerosis in Latin America. Are McDonald's criteria really applicable?]. Rev Mex Neuroci. 2007;8(1):49-56.

0     

Suarez GA, Hutton GJ, Rivera VM. Optic neuritis: Relation with multiple sclerosis. Acta Neurol Colomb. 2007;23:141-6.

0     

Suarez GA, Lotze TE, Hutton GJ, Rivera VM. Multiple sclerosis in the pediatric population. Acta Neurol Colomb. 2007;23:134-40.

64

Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):705-9. PMID: 17401392.

0     

Zhu W, Xu P, Cuascut FX, Hall AK, Oxford GS. Activin acutely sensitizes dorsal root ganglion neurons and induces hyperalgesia via PKC-mediated potentiation of transient receptor potential vanilloid I. J Neurosci. 2007;27(50):13770-80. PMID: 18077689.

118

Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):769-74. PMID: 17263005.

0     

Carra A, Rivera-Olmos V, Arcega R, Gabbai A, Haussen SR, Luetic G, et al. [The treatment of multiple sclerosis in Latin America: Current practice and optimal standards. The findings of a survey among neurologists at an interactive workshop]. Rev Neurol. 2006;42(7):399-407. PMID: 16602056.

2

Skromne E, Rivera VM, Ontaneda D, Ordonez L. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology. 2006;66(11):1787-8; author reply 1787-8. PMID: 16769975.

0     

Hutton G, Miller JR, Radue EW. MR finds widespread clinical use in MS diagnosis, management. Diagn Imaging. 2005;27:36-45.

0     

Hutton G, Miller JR, Radue EW. Multiple sclerosis: MRI in diagnosis, management, and monitoring. Appl Neurol. 2005;6(26-35):.

0     

Hutton G. Does "benign multiple sclerosis" really exist? Pract Neurol. 2005;4(3):27-9.

2

Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2005;64(12):2163. PMID: 15985607.

9

Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 2005;19(9):725-7. PMID: 16195186.

2

Rivera VM. The terms Latino and Anglo and tendency to early Alzheimer disease. Arch Neurol. 2005;62(11):1787; author reply 1787-8. PMID: 16286562.

0     

Rivera-Olmos VM, Lozano JA. [Cogan's syndrome: Neurological manifestations. Case report and review of literature]. Rev Mex Neuroci. 2005;6(1):97-101.

14

Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005;56:273-302. PMID: 15660513.

33

Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S3-11. PMID: 15596734.

0     

Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77-83. PMID: 14700647.

0     

Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004;61(9):1386-9. PMID: 15364684.

50

Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63(12 Suppl 6):S33-40. PMID: 15623669.

58

Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-39. PMID: 15223245.

16

Hong J, Zang YC, Li S, Rivera VM, Zhang JZ. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol. 2004;34(3):870-81. PMID: 14991617.

0     

Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004;61(10):1538-41. PMID: 15477507.

0     

Rivera VM. Esclerosis multiple: evidencias, genericos y similares. Rev Mex Neuroci. 2004;5(4):286-7.

0     

Rivera-Olmos VM, Hutton GJ, Breitbach WT. Discrepancia entre clinica e imagen: Esclerosis multiple en fase intermedia. Presentacion de un caso y revision del tema [Discrepancy between clinics and image techniques: Intermediate phase of multiple sclerosis. A case report and review of the literature]. Rev Mex Neuroci. 2004;5(2):158-62.

73

Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. PMID: 14985264.

104

Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004;172(8):5120-7. PMID: 15067096.

22

Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10(5):499-506. PMID: 15471364.

0     

Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944-9. PMID: 12860795.

161

Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61(5):602-11. PMID: 12963748.

39

Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Jr, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003;61(6):848-50. PMID: 14504338.

2

Rivera VM. [Deciding on treatment in multiple sclerosis]. Rev Neurol. 2003;36(1):80-5. PMID: 12577220.

149

Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003;53(2):189-97. PMID: 12557285.

0     

Velazquez-Quintana M, Macias-Islas MA, Rivera-Olmos V, Lozano-Zarate J. [Multiple sclerosis in Mexico: A multicentre study]. Rev Neurol. 2003;36(11):1019-22. PMID: 12808495.

28

Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003;137(1-2):144-53. PMID: 12667659.

21

Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003;15(9):1073-80. PMID: 12917259.

37

Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002;8(3):237-42. PMID: 12120696.

0     

Rivera VM. II Congreso de LACTRIMS. Rev Neurol. 2002;35(12):1175-6.

9

Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunology. 2002;107(4):403-10. PMID: 12460184.

52

Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002;76(12):6147-54. PMID: 12021348.

67

Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol. 2002;124(1-2):106-14. PMID: 11958828.

40

Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002;24(12):1998-2021. PMID: 12581542.

49

Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, et al. T cell vaccination in multiple sclerosis: Results of a preliminary study. J Neurol. 2002;249(2):212-8. PMID: 11985389.

82

Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology. 2001;57(2):239-45. PMID: 11182328.

11

Rivera VM, Cabrera JA. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001;57(5):937-8. PMID: 11552042.

1

Rivera VM. [Neuroimaging in multiple sclerosis]. Rev Neurol. 2001;32(3):283-5. PMID: 11310287.

3

Rivera VM. [Pharmacologic treatment of multiple sclerosis]. Rev Neurol. 2001;32(3):285-8. PMID: 11310288.

0     

Rivera VM. La decada del cerebro. Neurociencia. 2001;2(13):131.

43

Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001;31(3):907-17. PMID: 11241296.

82

Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001;112(1-2):174-80. PMID: 11108946.

39

Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000;165(12):6858-64. PMID: 11120809.

0     

Rivera VM, Cabrera JA. La Esclerosis Multiple en Latino America. MEDICO Interamericano. 2000;19(10):458-65.

1

Rivera VM. [The treatment of multiple sclerosis with beta-interferon 1a]. Rev Neurol. 2000;31(5):470-1. PMID: 11027100.

0     

Rivera VM. Grupo de Estudio de EM (Mexico): Uso de Agentes Modificadores de la Enfermedad. Neurociencia. 2000;3:29-30.

0     

Rivera VM. Introduccion al Simposio Latino Americano. Rev Neurol. 2000;31(5):469.

29

Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000;12(12):1641-50. PMID: 11099303.

59

Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000;164(8):4011-7. PMID: 10754292.

51

Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000;30(3):908-13. PMID: 10741408.

73

Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000;123 ( Pt 9):1874-82. PMID: 10960051.

50

Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000;55(3):397-404. PMID: 10932275.

54

Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, et al. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol. 1999;163(6):3530-8. PMID: 10477628.

65

Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999;98(2):201-7. PMID: 10430053.

98

Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53(8):1692-7. PMID: 10563614.

29

Singh RA, Zang YC, Shrivastava A, Hong J, Wang GT, Li S, et al. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J Immunol. 1999;163(12):6393-402. PMID: 10586029.

74

Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999;29(5):1692-700. PMID: 10359124.

24

Kozovska M, Zang YC, Aebischer I, Lnu S, Rivera VM, Crowe PD, et al. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: Structural requirements and clinical implications. Eur J Immunol. 1998;28(6):1894-901. PMID: 9645371.

14

Zang YC, Kozovska M, Aebischer I, Li S, Boehme S, Crowe P, et al. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. Int Immunol. 1998;10(7):991-8. PMID: 9701037.

63

Jerger J, Alford B, Lew H, Rivera V, Chmiel R. Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. Ear Hear. 1995;16(5):482-98. PMID: 8654903.

0     

Trujillo JR, Garcia-Ramos G, Novak IS, Rivera VM, Huerta E, Essex M. Neurologic manifestations of AIDS: A comparative study of two populations from Mexico and the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(1):23-9. PMID: 8548343.

120

Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, et al. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: The role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994;20(3):434-44; discussion 442-3. PMID: 8084037.

255

Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, et al. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991;13(1):36-45; discussion 45-6. PMID: 1987395.

85

Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJNR Am J Neuroradiol. 1990;11(5):987-91. PMID: 2121005.

44

Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJR Am J Roentgenol. 1990;155(6):1303-7. PMID: 2122684.

14

Rivera VM. Safety of intrathecal steroids in multiple sclerosis. Arch Neurol. 1989;46(7):718-9. PMID: 2535600.

0     

Olmos Garcia de Alba G, Gamboa Marrufo JD, Rengifo Ramos O, Calderon FE, Espinosa Tanguna R, Rivera Olmos VM, et al. Rett's syndrome with Lennox-Gastaut pattern. Clin Electroencephalogr. 1987;18(4):187-90. PMID: 3117441.

41

Jerger JF, Oliver TA, Chmiel RA, Rivera VM. Patterns of auditory abnormality in multiple sclerosis. Audiology. 1986;25(4-5):193-209. PMID: 3566629.

45

Rivera VM, Meyer JS, Hata T, Ishikawa Y, Imai A. Narcolepsy following cerebral hypoxic ischemia. Ann Neurol. 1986;19(5):505-8. PMID: 3717910.

3

Rivera VM. Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986;79(8):217-32. PMID: 3520524.

0     

Rivera VM. Stroke. A guide to differential diagnosis and prevention. Postgrad Med. 1985;77(4):81-8. PMID: 3975191.

51

Hannley M, Jerger JF, Rivera VM. Relationships among auditory brain stem responses, masking level differences and the acoustic reflex in multiple sclerosis. Audiology. 1983;22(1):20-33. PMID: 6830528.

8

Jerger J, Hannley M, Rivera V. Auditory brainstem response and the masking level difference. Ann N Y Acad Sci. 1982;388:466-70. PMID: 6953883.

8

Rivera VM. Intraspinal steroid therapy. Neurology. 1981;31(8):1060-1. PMID: 6894967.

17

Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. Arch Neurol. 1980;37(4):201-3. PMID: 7362484.

26

Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979;6(3):227-31. PMID: 534421.

5

Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: A new syndrome. Trans Am Neurol Assoc. 1978;103:116-8. PMID: 757033.

0     

Jankovic J, Rivera VM. Hereditary myoclonus and progressive spinal muscular atrophy: A new syndrome. Ann Neurol. 1978;4(2):170-1.

2

Perez FI, Hruska NA, Stell RL, Rivera VM. Computerized assessment of memory performance in dementia. Can J Neurol Sci. 1978;5(3):307-12. PMID: 359117.

0     

Rivera VM, Patten BM. Neuromyopathy in malignant hyperthermia. J Clin Psychiatry. 1978;39(1):67-71. PMID: 580262.

0     

Rivera VM. Acute hypokalemic myopathy in alcoholism. Arch Neurol. 1978;35(9):619. PMID: 687190.

1

Guido EM, Rivera VM. Precordialgia as a manifestation of vertebrobasilar insufficiency. J Am Geriatr Soc. 1977;25(10):463-5. PMID: 903546.

2

Rivera VM. Viruses and multiple sclerosis. Jama. 1977;238(12):1247. PMID: 578169.

0     

Rodriguez J, Rivera VM. Risk factors in stroke in a Mexican-American population (Houston). Neurol Neurocir Psiquiatr. 1977;18(2-3 Suppl):225-34. PMID: 616532.

1

Rivera VM. Letter: Symptomatic care of patients with amyotrophic lateral sclerosis. Jama. 1976;235(24):2584-5. PMID: 946858.

12

Perez FI, Gay JR, Taylor RL, Rivera VM. Patterns of memory performance in the neurologically impaired aged. Can J Neurol Sci. 1975;2(4):347-55. PMID: 1201525.

0     

Perez FI, Rivera VM, Meyer JS, Gay JR, Taylor RL, Mathew NT. Analysis of intellectual and cognitive performance in patients with multi-infarct dementia, vertebrobasilar insufficiency with dementia, and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1975;38(6):533-40. PMID: 1151420.

10

Rivera VM, Breitbach WB, Swanke L. Letter: Dantrolene in amyotrophic lateral sclerosis. Jama. 1975;233(8):863-4. PMID: 1173890.

10

Rivera VM, Keichian AH, Oliver RE. Persistent parkinsonism following neuroleptanalgesia. Anesthesiology. 1975;42(5):635-7. PMID: 1130732.

0     

Meyer JS, Bauer RB, Rivera-Olmos VM, Nolan DC, Lerner AM. Herpesvirus hominis encephalitis. Neurological manifestations and use of idoxuridine. Arch Neurol. 1970;23(5):438-50. PMID: 4319497.